INVESTIGATIONS OF ALPHA-SYNUCLEIN IN PARKINSONIAN PATHOGENESIS

$35,848P41FY2010RRNIH

University Of California, San Diego, La Jolla CA

Investigators

Linked publications, trials & patents

Paper 34363809 Paper 34258598 Paper 34211011 Paper 33065099 Paper 27872255 Paper 27522477 Paper 26773602 Paper 26743035 Paper 26721881 Paper 26411340 Paper 26335304 Paper 26247724 Paper 26240339 Paper 26120963 Paper 26108722 Paper 25659516 Paper 25557093 Paper 25416358 Paper 25200600 Paper 25197615 Paper 24979790 Paper 24931576 Paper 24902900 Paper 24740641 Paper 24556578 Paper 24529444 Paper 24454724 Paper 24337820 Paper 24323412 Paper 24323301 Paper 24322429 Paper 24252469 Paper 24091663 Paper 24069262 Paper 24030101 Paper 24013648 Paper 23967136 Paper 23926251 Paper 23859254 Paper 23746531 Paper 23703906 Paper 23671069 Paper 23664612 Paper 23589582 Paper 23577164 Paper 23574738 Paper 23561539 Paper 23536074 Paper 23407494 Paper 23392688 Paper 23390418 Paper 23339176 Paper 23303931 Paper 23288995 Paper 23252598 Paper 23246342 Paper 23203874 Paper 23187627 Paper 23138851 Paper 23087000 Paper 23086203 Paper 23063122 Paper 23056591 Paper 23055955 Paper 23035660 Paper 23028948 Paper 22982782 Paper 22958918 Paper 22937143 Paper 22872700 Paper 22857927 Paper 22833114 Paper 22689074 Paper 22684938 Paper 22644867 Paper 22608008 Paper 22495592 Paper 22396594 Paper 22376256 Paper 22204315 Paper 22158479 Paper 22108385 Paper 22080837 Paper 22052464 Paper 22003676 Paper 21949692 Paper 21933715 Paper 21903074 Paper 21867881 Paper 21829502 Paper 21788351 Paper 21780303 Paper 21745647 Paper 21724952 Paper 21641550 Paper 21504163 Patent 7952073 Patent 7262411 Patent 5594253 Patent 5401964

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our goals in this collaboration are to investigate the role of alpha-synuclein and hydroxybutyrate dehydrogenase type 2 (BDH2) in the progression of Parkinson disease (PD) and assess putative therapeutic strategies. We intend to apply the tetracysteine (4Cys)-labeling system developed at NCMIR to track, at multiple resolution scales, the trafficking of proteins associated with PD. This work will draw upon the techniques being advanced at NCMIR, including improved 4Cys approaches, correlated live imaging-3D electron microscopic analysis, and high-resolution electron tomographic reconstruction.

View original record on NIH RePORTER →